

COGNITIVE

# Selank

TP-7 Tuftsin Analogue

Heptapeptide anxiolytic nootropic. GABAergic tone modulation without sedation or dependence.

**MECHANISM**

GABAergic modulation; BDNF and enkephalin upregulation

**DOSAGE**

250–500 mcg/day SC or intranasal

**HALF-LIFE**

<10 min plasma (central effects persist)

**FORMAT**

Lyophilised powder

**BATCH**

NU-SEL-2148

**LOT**

542148

**CAS**

129954-34-3

**FORMULA**

C33H57N11O9

**ISSUED**

2025-08-08

**RETEST**

2026-08-08

## OVERVIEW

Selank is a heptapeptide anxiolytic (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics, Russian Academy of Sciences, as a tuftsin analogue. Unlike benzodiazepines, it modulates GABAergic tone without sedation, dependence, or cognitive blunting.

## MECHANISM OF ACTION

GABAergic modulation; BDNF and enkephalin upregulation

## KEY RESEARCH BENEFITS

- Anxiolytic without sedation or dependence
- BDNF upregulation — neuroplasticity enhancement
- Improved working memory and learning
- Stable mood without emotional blunting
- Antiviral immunomodulatory properties

## RESEARCH NOTES

Russian Phase III trials (N = 60+) show significant GAD symptom reduction vs placebo. BDNF serum elevation of 35% documented. Registered medicine in Russia since 2009.

## STORAGE & STABILITY

Lyophilised: -20 °C, stable >=24 months. Reconstituted: 2–8 °C, use within 14 days.